Clinical Trials on Polyradiculoneuropathy in Netherlands

Total 10 results

UCB Biopharma SRL

Completed

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (MyCIDPchoice)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom
Bioverativ, a Sanofi company

Active, not recruiting

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Canada, Spain, China, Italy, United States, France, Germany, Netherlands, Poland, Serbia
Novartis Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation

Completed

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, United States, Belgium, Germany, Italy, Israel, Australia, France, United Kingdom, Netherlands, Czechia, Japan, Canada, Greece, Poland
CSL Behring

Completed

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Japan, Australia, Canada, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
CSL Behring
ICON Clinical Research

Completed

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Polyradiculoneuropathy | Chronic Inflammatory Demyelinating Polyneuropathy

United States, Australia, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Spain, United Kingdom
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey
argenx

Completed

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Hansa Biopharma AB

Completed

A Study of Imlifidase in Patients With Guillain-Barré Syndrome

Guillain-Barré Syndrome (GBS)

France, Netherlands, United Kingdom
Erasmus Medical Center

Active, not recruiting

International Guillain-Barré Syndrome Outcome Study (IGOS)

Guillain-Barré Syndrome | Miller Fisher Syndrome

United States, Netherlands, United Kingdom, Bangladesh, Australia, Denmark, China, France, Germany, Spain, Argentina, Italy, Puerto Rico, South Africa, Belgium, Switzerland, Canada, Greece, Japan, Malaysia, Taiwan

Clinical Trials on Polyradiculoneuropathy in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations